NCT00413959 - VELCADE,Rituximab,Cyclophosphamide and Decadron | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Lymphoma, Non-HodgkinLymphoma, B-Cell

Interventions

DRUG

VELCADE®

1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.

DRUG

Rituximab

375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.

DRUG

Cyclophosphamide

400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.

DRUG

Decadron

40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23

Trial Locations (2)

Oncology Specialists, S.C, Park Ridge

Onocology Specialists, S.C, Niles